What's Roche's battle plan for Ventana?

Roche may be plenty confident of eventually winning Ventana, but some legal experts say the Swiss pharma giant faces a big stumbling block. To stave off Roche, Ventana invoked a poison pill, and Roche in turn filed suit to invalidate it. But the court presiding over that suit hasn't lifted a poison pill since the late 1980s, and M&A lawyers say it's not likely to now.

Meanwhile, Roche may have other options. It could mount a proxy fight to bring in a management team willing to deal. Though Ventana's board elections are staggered, so only a few members are up for election each year, the shareholders could push through a new rule and elect an entirely new board. Voilà! Merger.

Roche has extended its $75-per-share offer again, this time through January 17. Ventana's poison pill expires in March, and the company's annual meeting is scheduled for two months later.

- check out this report
- see Roche's extension of the Ventana offer

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.